{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:20:23Z","timestamp":1770416423742,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with HER2-positive, stage I\u2013III invasive breast cancer received six courses of trastuzumab (8\u00a0mg\/kg loading dose, then 6\u00a0mg\/kg, day 1), docetaxel (75\u00a0mg\/m<jats:sup>2<\/jats:sup>, day 1), and carboplatin (area under the curve: 6, day 1) every 3\u00a0weeks. The primary endpoint was pathological complete response (pCR) of both breast and axillary lymph node disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty patients were enrolled in this study. Median age was 58 (range 32\u201375) years. All patients underwent definitive surgery. Thirty-three (66%) patients completed the chemotherapy course, while the treatment was delayed or discontinued in the other 17 (34%) patients because of adverse events (AEs). The pCR rate was 52%; the overall response rate was 66%. Grade 3\/4 AEs due to nonhematological toxicity were anorexia (4%), diarrhea (2%), and rash (2%), and those due to hematological toxicity were neutropenia (36%), anemia (12%), and thrombocytopenia (2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although the triweekly six-course regimen of TCbH achieved a high pCR rate, hematological AEs frequently occurred during the latter part of the chemotherapy course. One-third of patients experienced delayed or discontinued chemotherapy.<\/jats:p>\n                <jats:p>Clinical registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.org.au\">http:\/\/www.umin.org.au<\/jats:ext-link>UMIN000013513.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-017-1136-8","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T11:31:09Z","timestamp":1495711869000},"page":"880-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3\u00a0weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety"],"prefix":"10.1007","volume":"22","clinical-trial-number":[{"clinical-trial-number":"umin000013513","registry":"10.18810\/umin-japan"}],"author":[{"given":"Ikuko","family":"Sugitani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shigekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Hirokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misono","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Fujiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940\u20131949","journal-title":"J Clin Oncol"},{"key":"1136_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172","journal-title":"Lancet"},{"key":"1136_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","volume":"15","author":"L Gianni","year":"2014","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15:640\u2013647","journal-title":"Lancet Oncol"},{"key":"1136_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25\u201332","journal-title":"Lancet Oncol"},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","volume":"15","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Holmes AP, Piccart-Gebhart M et al (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15:1137\u20131146","journal-title":"Lancet Oncol"},{"key":"1136_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clbc.2011.04.002","volume":"11","author":"DA Yardley","year":"2011","unstructured":"Yardley DA, Raefsky E, Castillo R et al (2011) Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2\u00a0+\u00a0breast cancer. Clin Breast Cancer 11:297\u2013305","journal-title":"Clin Breast Cancer"},{"key":"1136_CR7","doi-asserted-by":"crossref","unstructured":"Yardley DA, Zubkus JD, Eakle JF et al (2015) Neoadjuvant ixabepilone\/carboplatin\/trastuzumab in HER2-positive operable breast cancer: a phase II trial of the Sarah Cannon Research Institute. Clin Breast Cancer 15:251\u2013258","DOI":"10.1016\/j.clbc.2014.09.007"},{"key":"1136_CR8","first-page":"1969","volume":"10","author":"L Huang","year":"2015","unstructured":"Huang L, Chen S, Yao L et al (2015) Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomed 10:1969\u20131975","journal-title":"Int J Nanomed"},{"key":"1136_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283","journal-title":"N Engl J Med"},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-016-4098-z","volume":"162","author":"I Echavarria","year":"2017","unstructured":"Echavarria I, Granja M, Bueno C et al (2017) Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat 162:181\u2013189","journal-title":"Breast Cancer Res Treat"},{"key":"1136_CR11","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2006.09.9994","volume":"25","author":"BP Coudert","year":"2007","unstructured":"Coudert BP, Largillier R, Arnould L et al (2007) Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GENT(A)-1 trial. J Clin Oncol 25:2678\u20132684","journal-title":"J Clin Oncol"},{"key":"1136_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10147-011-0287-2","volume":"17","author":"S Ueda","year":"2012","unstructured":"Ueda S, Saeki T, Shigekawa T et al (2012) 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol 17:276\u2013282","journal-title":"Int J Clin Oncol"},{"key":"1136_CR13","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"1136_CR14","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205","journal-title":"J Clin Oncol"},{"key":"1136_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1136_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12282-007-0016-x","volume":"15","author":"M Kurosumi","year":"2008","unstructured":"Kurosumi M, Akashi-Tanaka S, Akiyama F et al (2008) Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer 15:5\u20137","journal-title":"Breast Cancer"},{"key":"1136_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3816\/CBC.2005.n.003","volume":"5","author":"J Hurley","year":"2005","unstructured":"Hurley J, Reis I, Silva O et al (2005) Weekly docetaxel\/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer 5:447\u2013454","journal-title":"Clin Breast Cancer"},{"key":"1136_CR18","unstructured":"Mehta RST, Hsiang D et al (2005) High pathological complete remission rates with paclitaxel and carbolpatin, trastuzumab following dose dense doxorubicin and cyclophosphamide in AC supported by GM-CSF in breast cancer\u2014a phase 2 study. Breast Cancer Res Treat 89:S225"},{"issue":"29","key":"1136_CR19","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","volume":"32","author":"S Loibl","year":"2014","unstructured":"Loibl S, von Minckwitz G, Schneeweiss A et al (2014) PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 32(29):3212\u20133220","journal-title":"J Clin Oncol"},{"issue":"8","key":"1136_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/annonc\/mdw197","volume":"27","author":"S Loibl","year":"2016","unstructured":"Loibl S, Majewski I, Guarneri V et al (2016) PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol 27(8):1519\u20131525","journal-title":"Ann Oncol"},{"key":"1136_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-014-2947-1","volume":"145","author":"M Ando","year":"2014","unstructured":"Ando M, Yamauchi H, Aogi K et al (2014) Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide\/epirubicin\/5-fluorouracil as neoadjuvant chemotherapy for stage II\/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 145:401\u2013409","journal-title":"Breast Cancer Res Treat"},{"key":"1136_CR22","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW et al (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525\u20133533","journal-title":"J Clin Oncol"},{"key":"1136_CR23","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","volume":"21","author":"RB Costa","year":"2010","unstructured":"Costa RB, Kurra G, Greenberg L et al (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21:2153\u20132160","journal-title":"Ann Oncol"},{"key":"1136_CR24","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796\u20131804","journal-title":"J Clin Oncol"},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-013-2444-y","volume":"138","author":"EA Perez","year":"2013","unstructured":"Perez EA, Press MF, Dueck AC et al (2013) Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138:99\u2013108","journal-title":"Breast Cancer Res Treat"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-017-1136-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T14:20:57Z","timestamp":1628605257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-017-1136-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1136-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]},"assertion":[{"value":"13 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Toshiaki Saeki received lecture fees from Chugai Pharmaceutical Co., Ltd. The other authors declare that they had no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}